Comparing new treatments for idiopathic pulmonary fibrosis - a network meta-analysis

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Loveman, Emma ^a   Copley, Vicky R ^a   Scott, David A ^b   Colquitt, Jill L ^a   Clegg, Andrew J ^a   O'Reilly, Katherine M A ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b ICON PLC   (United Kingdom)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Idiopathic pulmonary fibrosis; Network meta analysis; Systematic review

Indexed keywords

ACETYLCYSTEINE; NINTEDANIB; PIRFENIDONE; PLACEBO; ENZYME INHIBITOR; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE; SCAVENGER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; COMPARATIVE STUDY; IDIOPATHIC PULMONARY FIBROSIS;

ACETYLCYSTEINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENZYME INHIBITORS; FREE RADICAL SCAVENGERS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PYRIDONES; TREATMENT OUTCOME;

EID: 84976532212     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0034-y     Document Type: Article

References (28)

1. Kim DS, Collard HR, King Jr TE. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3:285-92.
2. American Cancer Society. Cancer Facts and Figures 2010. 2010. 13-6-2014
3. Costabel U. Idiopathic pulmonary fibrosis: recent milestones in disease management. Eur Respir Rev. 2012;21:140.
4. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760-9.
5. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821-9.
6. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-7.
7. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92.
8. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.
9. Hunninghake GM. A new hope for idiopathic pulmonary fibrosis. NEJM. 2014;370:2142-3.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). BMJ. 2009;339:b2535.
11. Loveman E, Colquitt JL, Copley V, Scott DA, Clegg A, Richeldi L, et al. Treatments for idiopathic pulmonary fibrosis: an updated systematic review and network meta-analysis. PROSPERO: International prospective register of systematic reviews. 2014
12. Loveman E, Copley V, Colquitt JL, Scott D, Clegg A, Jones J, et al. The clinical and cost effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess, 2015;19:20.
13. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care, Third edition. York, UK: York Publishing Services Ltd., CRD; 2009.
14. Caldwell D, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897-900.
15. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607-17.
16. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med. 2005;24:2401-28.
17. Salanti G, Marinho V, Higgins JPT. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol. 2009;62:857-64.
18. Egger M, Davey Smith G, Altman DG. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ Books; 2001.
19. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000;19:3127-31.
20. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7:434-55.
21. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B. 2002;64:583-639.
22. Raghu G, Anstrom KJ, King J, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968-77.
23. The Idiopathic Pulmonay Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2093-101.
24. Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology. 2012;17:467-77.
25. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-87.
26. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, et al. Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium. Chest. 2011;140:221-9.
27. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
28. Mills EJ, Thorlund K, Ionnidis JPA. Demystifying trial networks and network meta-analysis. BMJ. 2013;346:f2914.